Bio Key International Inc 10-Q for FY2026 Q3
Bio Key International Inc (BKYI)
About this 10-Q
Bio Key International Inc filed this 10-Q on November 13, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
BIO-KEY INTERNATIONAL, INC. reported nine-month revenue of 5,548,305, net loss of 1,667,972 and operating cash outflow of 2,634,682. Management said substantial doubt exists about its ability to continue as a going concern. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $1.48M
- down 4.3% from $1.55M a year earlier
- Net loss
- $886.08K
- compared with a net loss of $964.85K a year earlier
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
| | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
or
| | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Transition Period from to
Commission file number
BIO-KEY INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
| | |
| (State or Other Jurisdiction of Incorporation of Organization) | (IRS Employer Identification Number) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| | | |
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ |
| Accelerated filer ☐ |
| |
| Smaller Reporting Company |
|
| Emerging growth company | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined by rule 12b-2 of the Exchange Act) Yes
Number of shares of Common Stock, $.0001 par value per share, outstanding as of November 12, 2026, is
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
INDEX
PART I -- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventory | ||||||||
| Prepaid expenses and other | ||||||||
| Total current assets | ||||||||
| Equipment and leasehold improvements, net | ||||||||
| Capitalized contract costs, net | ||||||||
| Deposits and other assets | ||||||||
| Operating lease right-of-use assets | ||||||||
| Investments | ||||||||
| Intangible assets, net | ||||||||
| Total non-current assets | ||||||||
| TOTAL ASSETS | $ | $ | ||||||
| LIABILITIES | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued liabilities | ||||||||
| Note payable | ||||||||
| Government loan – BBVA Bank, current portion | ||||||||
| Deferred revenue, current | ||||||||
| Operating lease liabilities, current portion | ||||||||
| Total current liabilities | ||||||||
| Deferred revenue, long term | ||||||||
| Deferred tax liability | ||||||||
| Operating lease liabilities, net of current portion | ||||||||
| Total non-current liabilities | ||||||||
| TOTAL LIABILITIES | ||||||||
| Commitments and Contingencies | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Common stock — authorized, shares; issued and outstanding; of $ par value at September 30, 2026 and at December 31, 2025, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated other comprehensive income (loss) | ( | ) | ||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | ||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | $ | ||||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split, which was effective April 30, 2026.
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | ||||||||||||||||
| Services | $ | $ | $ | $ | ||||||||||||
| License fees | ||||||||||||||||
| Hardware | ||||||||||||||||
| Total revenues | ||||||||||||||||
| Costs and other expenses | ||||||||||||||||
| Cost of services | ||||||||||||||||
| Cost of license fees | ||||||||||||||||
| Cost of hardware | ||||||||||||||||
| Cost of hardware - reserve | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total costs and other expenses | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | ||||||||||||||||
| Research, development and engineering | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | ||||||||||||||||
| Loan fee amortization | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other income (expense), net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss before provision for income tax | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Provision for income taxes | ||||||||||||||||
| Net loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Deemed dividend related to warrant inducement | ( | ) | ( | ) | ||||||||||||
| Net loss available to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Comprehensive loss: | ||||||||||||||||
| Net loss available to common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Other comprehensive loss – foreign currency translation adjustment | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Comprehensive loss | $ | ( | ) | $ | ( | ) | $ | ) | $ | ( | ) | |||||
| Basic and diluted loss per common share | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split, which was effective April 30, 2026.
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
| Accumulated | ||||||||||||||||||||||||
| Additional | Other | |||||||||||||||||||||||
| Common Stock | Paid-in | Comprehensive | Accumulated | |||||||||||||||||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Total | |||||||||||||||||||
| Balance as of January 1, 2026 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Issuance of restricted stock to employees | ||||||||||||||||||||||||
| Restricted stock forfeited | ( | ) | ||||||||||||||||||||||
| Foreign currency translation adjustment | - | ( | ) | ( | ) | |||||||||||||||||||
| Share-based compensation | - | |||||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||||||
| Balance as of March 31, 2026 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Issuance of common stock for Employee Stock Purchase Plan | ||||||||||||||||||||||||
| Share-based compensation for employee stock plan | - | |||||||||||||||||||||||
| Foreign currency translation adjustment | - | ( | ) | ( | ) | |||||||||||||||||||
| Share-based compensation | - | |||||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||||||
| Balance as of June 30, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
| Issuance of common stock for repayment of note payable and accrued interest | ||||||||||||||||||||||||
| Restricted stock forfeited | ( | ) | ||||||||||||||||||||||
| Issuance of restricted common stock to employees and directors | ||||||||||||||||||||||||
| Foreign currency translation adjustment | - | ( | ) | ( | ) | |||||||||||||||||||
| Deemed dividends related to warrant inducement | - | ( | ) | |||||||||||||||||||||
| Share-based compensation | - | |||||||||||||||||||||||
| Exercise of warrants | ||||||||||||||||||||||||
| Issuance costs | - | ( | ) | ( | ) | |||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||||||
| Balance as of September 30, 2026 | $ | $ | $ | ( | ) | $ | ( | ) | $ | |||||||||||||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split, which was effective April 30, 2026.
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
| Accumulated | ||||||||||||||||||||||||
| Additional | Other | |||||||||||||||||||||||
| Common Stock | Paid-in | Comprehensive | Accumulated | |||||||||||||||||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Total | |||||||||||||||||||
| Balance as of January 1, 2025 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Issuance of common stock for directors’ fees | - | |||||||||||||||||||||||
| Issuance of restricted stock to employees | ||||||||||||||||||||||||
| Issuance of common stock for repayment of debt | ||||||||||||||||||||||||
| Restricted stock forfeited | ( | ) | ||||||||||||||||||||||
| Exercise of warrants | ||||||||||||||||||||||||
| Foreign currency translation adjustment | - | |||||||||||||||||||||||
| Share-based compensation | - | |||||||||||||||||||||||
| Issuance costs | - | ( | ) | ( | ) | |||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||||||
| Balance as of March 31, 2025 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Issuance of common stock for directors’ fees | ||||||||||||||||||||||||
| Issuance of restricted stock to employees | ||||||||||||||||||||||||
| Issuance of common stock for repayment of debt | ||||||||||||||||||||||||
| Restricted stock forfeited | ( | ) | ||||||||||||||||||||||
| Issuance of common stock for Employee Stock Purchase Plan | ||||||||||||||||||||||||
| Share-based compensation for Employee Stock Purchase Plan | - | |||||||||||||||||||||||
| Foreign currency translation adjustment | - | |||||||||||||||||||||||
| Exercise of warrants | ( | ) | ||||||||||||||||||||||
| Share-based compensation | - | |||||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||||||
| Balance as of June 30, 2025 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
| Issuance of common stock for repayment of debt | ||||||||||||||||||||||||
| Issuance of restricted common stock to employees and directors | ( | ) | ||||||||||||||||||||||
| Foreign currency translation adjustment | - | ( | ) | ( | ) | |||||||||||||||||||
| Share-based compensation | - | |||||||||||||||||||||||
| Net loss | - | ( | ) | ( | ) | |||||||||||||||||||
| Balance as of September 30, 2025 | $ | $ | $ | $ | ( | ) | $ | |||||||||||||||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-10 reverse stock split, which was effective April 30, 2026.
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOW FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used for operating activities: | ||||||||
| Depreciation | ||||||||
| Amortization of intangible assets | ||||||||
| Amortization of capitalized contract costs | ||||||||
| Amortization of note payable | ||||||||
| Interest payable on note | ||||||||
| Reserve for inventory | ( | ) | ||||||
| Operating lease right-of-use assets | ||||||||
| Share and warrant-based compensation for employees and consultants | ||||||||
| Stock based directors’ fees | ||||||||
| Bad debts | ||||||||
| Change in assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ( | ) | ||||
| Due from factor | ||||||||
| Capitalized contract costs | ( | ) | ( | ) | ||||
| Inventory | ( | ) | ||||||
| Prepaid expenses and other | ( | ) | ( | ) | ||||
| Accounts payable | ( | ) | ( | ) | ||||
| Accrued liabilities | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ( | ) | ||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Capital expenditures | ( | ) | ( | ) | ||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| CASH FLOW FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from note payable | ||||||||
| Offering costs | ( | ) | ( | ) | ||||
| Proceeds for exercise of warrants | ||||||||
| Receipt of cash from employee stock purchase plan | ||||||||
| Repayment of government loan | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Effect of exchange rate changes | ( | ) | ( | ) | ||||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ( | ) | ||||||
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | ||||||||
| CASH AND CASH EQUIVALENTS, END OF PERIOD | $ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
SUPPLEMENTARY DISCLOSURES OF CASH FLOW INFORMATION
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash paid for: | ||||||||
| Interest | $ | $ | ||||||
| Noncash investing and financing activities | ||||||||
| Additions for operating lease right-of-use assets | $ | | $ | - | ||||
| Issuance of stock for repayment of note payable and accrued interest | $ | $ | ||||||
| Deemed dividends related to warrant inducement | $ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements.
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2026 (Unaudited)
| 1. | NATURE OF BUSINESS AND BASIS OF PRESENTATION |
Nature of Business
BIO-key International, Inc. and its wholly-owned subsidiaries (collectively, the “Company” or “BIO-key”), founded in 1993, develops and markets proprietary fingerprint identification biometric technology and software solutions and enterprise-ready identity access management solutions to commercial, government and education customers throughout the United States and internationally. The Company was a pioneer in developing automated, finger identification technology that supplements or complements other methods of identification and verification, such as personal inspection identification, passwords, tokens, smart cards, ID cards, PKI, credit cards, passports, driver’s licenses, OTP or other form of possession or knowledge-based credentialing. Additionally, advanced BIO-key® technology has been, and is, used to improve both the accuracy and speed of competing finger-based biometrics.
Basis of Presentation
The accompanying unaudited interim condensed consolidated financial statements include the accounts of BIO-key and include all normal and recurring adjustments which are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim consolidated financial statements and Rule 8-03 of Regulation S-X promulgated by the Securities and Exchange Commission (the “SEC”). The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year ending December 31, 2026. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the financial statements have been condensed or omitted. Intercompany accounts and transactions have been eliminated in consolidation.
In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all necessary adjustments, consisting only of those of a recurring nature, and disclosures to present fairly the Company’s financial position and the results of its operations and cash flows for the periods presented. These unaudited interim condensed consolidated financial statements should be read in conjunction with the financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025, filed with the SEC on June 15, 2026 from which the accompanying condensed consolidated balance sheet dated December 31, 2025 was derived.
Foreign Currencies
The Company accounts for foreign currency transactions pursuant to ASC 830, Foreign Currency Matters ("ASC 830”). The functional currency of the Company is the U. S. dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, monetary balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions and from the remeasurement of the monetary balance sheet items are recorded as gain (loss) on foreign currency transactions.
The functional currency of Swivel Secure Europe, SA is the Euro. Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. Revenues and expenses are translated using the average exchange rates prevailing throughout the respective periods. All transaction gains and losses from the measurement of monetary balance sheet items denominated in Euros are reflected in the statement of operations as appropriate. Translation adjustments are included in accumulated other comprehensive loss.
The functional currency of BIO-key Africa is the Naira, however, the majority of the Company's transactions are U. S. dollars. Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. An adjustment will be made for the current value of our bank account in Naira currency if the amount materially changes.
The functional currency of BIO-key Hong Kong is the Hong Kong Dollar (HKD). Under ASC 830, all assets and liabilities are translated into U. S. dollars using the current exchange rate at the end of each fiscal period. An adjustment will be made for the current value of our bank account in HKD currency if the amount materially changes.
Reverse Stock Split
All references to issued and outstanding shares for all periods reflect the 1-for-
Recently Issued Accounting Pronouncements
In October 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-06, “Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative” (“ASU 2023-06”). This ASU incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification (“ASC”). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of ASC Topics, allow users to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the ASC with the SEC’s regulations. The ASU has an unusual effective date and transition requirements since it is contingent on future SEC rule setting. If the SEC fails to enact required changes by June 30, 2027, this ASU is not effective for any entities. Early adoption is not permitted. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements and disclosures.
.
.
In November 2024, the FASB issued ASU 2024-03, “Income Statement: Reporting Comprehensive Income - Expense Disaggregation Disclosures,” which requires more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement, as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 (fiscal year beginning January 1, 2027 for the Company) and for interim periods within fiscal years beginning after December 15, 2027 (quarter ended March 31, 2028 for the Company). Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements.
In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements.” The amendments in this update clarify interim disclosure requirements and the applicability of Topic 270. This ASU requires a comprehensive list of interim disclosures to provide clarity about the current requirements, and includes a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The ASU further clarifies the applicability of Topic 270, the types of interim reporting, and the form and content of interim financial statements in accordance with GAAP. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 (quarter ended March 31, 2028 for the Company). The amendment can be applied using the prospective or retrospective transition approach for any or all prior periods presented in the financial statements. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-11 on its consolidated financial statements.
In December 2025, the FASB issued ASU 2025-12, “Codification Improvements.” Thirty-three issues are addressed in this ASU covering technical corrections, unintended application of the Codification, clarifications, and other minor improvements. This ASU is effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods (quarter ended March 31, 2027 for the Company). If an entity adopts the ASU in an interim period, it must adopt them as of the beginning of the annual reporting period that includes that interim reporting period. An entity may elect to early adopt the amendments on an issue-by-issue basis. The amendment can be applied using the prospective or retrospective transition approach for any or all prior periods presented in the financial statements and an entity may elect the transition method on an issue-by-issue basis. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2025-12 on its consolidated financial statements.
Recently Adopted Accounting Pronouncements
Effective January 1, 2026, the Company adopted ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”, which introduced a practical expedient that allows entities to assume that current conditions at the balance sheet date remain unchanged for the remaining life of the asset when developing reasonable and supportable forecasts. This eliminates the need to incorporate macroeconomic forecasts for short-term receivables. The adoption of ASU 2025-05 did not have a significant impact on the Company’s consolidated financial statements .
| 2. | GOING CONCERN |
In accordance with ASU No. 2014-15, "Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)", the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.
The Company has historically financed operations through access to the capital markets by issuing convertible debt securities, convertible preferred stock, common stock, and through factoring receivables. As of the date of this report, the Company does not have enough cash for twelve months of operations. The history of losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raise doubt about the Company's ability to continue as a going concern.
The accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern, and assumes continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon the Company’s ability to increase its revenue and meet its financing requirements on a continuing basis and become profitable in its future operations. The Company has lowered expenses through decreasing spending in marketing, and research and development. In order to mitigate the losses and improve cash flow, the Company is working on the following initiatives. The EMESA subsidiary is now only selling BIO-key and PortalGuard solutions that do not carry the previous license fee of 50% cost of sales and the inventory purchased for projects in Nigeria, which have been delayed in deployment, are being sold into other markets to generate additional cash. The accompanying condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
| 3. | REVENUE FROM CONTRACTS WITH CUSTOMERS |
Disaggregation of Revenue
The following tables summarize revenue from contracts with customers for the three-month periods ended September 30, 2026 and September 30, 2025:
| North | September 30, | |||||||||||||||||||
| America | Africa | EMESA* | Asia | 2026 | ||||||||||||||||
| Services | $ | $ | $ | $ | $ | |||||||||||||||
| License fees | ||||||||||||||||||||
| Hardware | ||||||||||||||||||||
| Total Revenues | $ | $ | $ | $ | $ | |||||||||||||||
| North | September 30, | |||||||||||||||||||
| America | Africa | EMESA* | Asia | 2025 | ||||||||||||||||
| Services | $ | $ | $ | $ | $ | |||||||||||||||
| License fees | ||||||||||||||||||||
| Hardware | ||||||||||||||||||||
| Total Revenues | $ | $ | $ | $ | $ | |||||||||||||||
The following tables summarize revenue from contracts with customers for the nine-month periods ended September 30, 2026 and September 30, 2025:
|
| North | September 30, | ||||||||||||||||||
| America | Africa | EMESA* | Asia | 2026 | ||||||||||||||||
| Services | $ | $ | $ | $ | $ | |||||||||||||||
| License fees | ||||||||||||||||||||
| Hardware | ||||||||||||||||||||
| Total Revenues | $ | $ | $ | $ | $ | |||||||||||||||
| North | September 30, | |||||||||||||||||||
| America | Africa | EMESA* | Asia | 2025 | ||||||||||||||||
| Services | $ | $ | $ | $ | $ | |||||||||||||||
| License fees | ||||||||||||||||||||
| Hardware | ||||||||||||||||||||
| Total Revenues | $ | $ | $ | $ | $ | |||||||||||||||
*EMESA – Europe, Middle East, South America
Deferred Revenue
Deferred revenue includes customer advances and amounts that have been paid by customer for which the contractual maintenance terms have not yet occurred. The majority of these amounts are related to maintenance contracts for which the revenue is recognized ratably over the applicable term, which generally is
| 4. | ACCOUNTS RECEIVABLE |
Accounts receivable are carried at original amount less an estimate made for credit losses based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for credit losses by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, current economic conditions and other relevant factors, including specific reserves for certain accounts. Accounts receivable are written off when deemed uncollectible.
Accounts receivable at September 30, 2026 and December 31, 2025 consisted of the following:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Accounts receivable | $ | $ | ||||||
| Allowance for credit losses | ( | ) | ( | ) | ||||
| Accounts receivable, net of allowances for credit losses | $ | $ | ||||||
Bad debt expenses are recorded in selling, general, and administrative expense.
| 5. | SHARE-BASED COMPENSATION |
The following table presents share-based compensation expenses included in the Company’s unaudited condensed interim consolidated statements of operations:
| Three Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Selling, general and administrative | $ | $ | ||||||
| Research, development and engineering | ||||||||
| $ | $ | |||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Selling, general and administrative | $ | $ | ||||||
| Research, development and engineering | ||||||||
| $ | $ | |||||||
| 6. | INVENTORY |
Inventory is stated at the lower of cost, determined on a first in, first out basis, or net realizable value. The Company periodically evaluates inventory items and establishes reserves for obsolescence accordingly. The Company also reserves for excess quantities, slow moving goods, and for other impairment of value based upon assumptions of future demand and market conditions. The reserve on inventory is due to slow moving inventory purchased for projects in Nigeria, and slow-moving inventory elsewhere. The Company has been selling these units in small quantities and continues to explore other markets and opportunities to sell the product. Inventory is comprised of the following as at September 30, 2026 and December 31, 2025:
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Finished goods | $ | $ | ||||||
| Fabricated assemblies | ||||||||
| Reserve on finished goods | ( | ) | ( | ) | ||||
| Total inventory | $ | $ | ||||||
7. INVESTMENTS
Equity Investment in Privately Held Company
On November 27, 2024, the Company purchased
The purchase agreement between the Company and Fiber Food contemplates collaboration between the parties regarding potential strategic and commercial transactions, including acquiring assets or equity interests in other operating companies, integrating the Company’s identity access management solutions into Fiber Food’s offerings, and introducing the Company to its customers, affiliates and business contacts who are potential users of the Company’s solutions, in each case pursuant to future definitive agreements on terms to be negotiated by the parties. The purchase agreement contains a standstill which prohibits the Company, Fiber Food, Boumarang and their respective affiliates and representatives for a period of two years, from, among other things, initiating any business combination, restructuring, tender offer, proposal to seek representation on the board of directors, or any proxy solicitation, instigating, encouraging or assisting any third party from doing any of the foregoing, or acquiring any debt or equity securities of any other party. In April of 2025, Boumarang acquired all intellectual property rights to the Wavedrone platform from Shore House IVF, a technology developer based in the Faroe Islands, for $
The Boumarang Shares constitute an investment in a privately held company for which there is no trading market and are carried at fair value. Fair value is the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use in pricing the asset or liability, such as inherent risk, non-performance risk and credit risk. The Company follows ASC Topic 820 – “Fair Value Measurement,” which establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy categorizes assets and liabilities measured at fair value into one of three different levels depending on the observability of the inputs employed in the measurement. The three levels are defined as follows:
Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2: Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability and inputs that are derived from observable market data by correlation or other means.
Level 3: Inputs for the asset or liability that are not based on observable market data (unobservable inputs).
The Boumarang Shares are classified as a Level 2 asset and have been valued based on a combination of recent sales of Boumarang common stock to third parties and a third party valuation applying a discounted cash flow analysis which included discounts for lack of control and lack of marketability, small company risk premium, and specific company risk premium based on Boumarang being an early-stage pre-revenue company. The lack of control and marketability discounts were based on published studies and transfer restrictions contained in Boumarang’s corporate governance documents.
Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Boumarang Shares may fluctuate from period to period and the fair value of the Boumarang Shares may differ significantly from the values that would have been used had a ready market existed for such shares and may differ materially from the values that the Company may ultimately realize. The early-stage pre-revenue status and unproven technology of Boumarang, Inc. raise uncertainties that could impact the recoverability of the investment in the Boumarang Shares.
Fair value measurement requires annual impairment testing for equity securities without readily determinable fair values. As of December 31, 2025, management recorded a
| 8. | COMMITMENTS AND CONTINGENCIES |
Litigation
From time to time, the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of September 30, 2026, the Company was not a party to any pending lawsuits.
| 9. | LEASES |
The Company leases office space in New Jersey, Minnesota, New Hampshire, Madrid and Hong Kong with lease termination dates in 2027 and 2029. The property leased in China is paid monthly as used, without a formal agreement. The following tables present the components of lease expense and supplemental balance sheet information related to the operating leases:
| 3 Months ended | 3 Months ended | |||||||
| September 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| Lease cost | ||||||||
| Total lease cost | $ | $ | ||||||
| 9 Months ended | 9 Months ended | |||||||
| September 30, | September 30, | |||||||
| 2026 | 2025 | |||||||
| Lease cost | ||||||||
| Total lease cost | $ | $ | ||||||
| September 30, | December 31, | |||||||
| Balance sheet information | 2026 | 2025 | ||||||
| Operating right-of-use assets | $ | $ | ||||||
| Operating lease liabilities, current portion | $ | $ | ||||||
| Operating lease liabilities, non-current portion | ||||||||
| Total operating lease liabilities | $ | $ | ||||||
| Weighted average remaining lease term (in years) – operating leases | ||||||||
| Weighted average discount rate – operating leases | % | % | ||||||
| Cash paid for amounts included in the measurement of operating lease liabilities for the nine months ended September 30, 2026 and 2025: | $ | $ | ||||||
Maturities of operating lease liabilities were as follows as of September 30, 2026:
| 2026 (3 months remaining) | $ | |||
| 2027 | ||||
| 2028 | ||||
| 2029 | ||||
| Total future lease payments | $ | |||
| Less: imputed interest | ( | ) | ||
| Total | $ |
| 10. | NOTES PAYABLE |
Note Purchase Agreement dated June 24, 2024
On June 24, 2024, the Company entered into and closed a note purchase agreement with Streeterville Capital, LLC (the "Lender") which provided for the issuance of a $
The principal amount of the 2024 Note was due 18 months following the date of issuance. Interest under the 2024 Note accrued at a rate of nine percent (
The 2024 Note was secured by a lien on substantially all of the Company’s assets and properties and the Company’s obligations under the 2024 Note were guaranteed by Pistol Star, Inc. (“Pistol”), a wholly owned subsidiary of the Company. The 2024 Note could be prepaid in whole or in part without penalty at any time. In the event that the Company received any proceeds in connection with any fundraising or financing transaction (including any warrant exercises), it would be required to make a mandatory prepayment equal to the lesser of (i) forty percent (
In the third quarter of 2024, the Company received gross proceeds of approximately $
Between January and September 2025, the Company entered into a number of Exchange Agreements with the holder of the 2024 Note pursuant to which it partitioned from the 2024 Note new promissory notes in the aggregate principal amount of $
Note Purchase Agreement dated September 30, 2025
On September 30, 2025, the Company entered into and closed a note purchase agreement with the Lender which provided for the issuance of a $
The principal amount of the 2025 Note is due 18 months following the date of issuance. Interest under the 2025 Note accrues at a rate of nine percent (
The 2025 Note is secured by a lien on substantially all of the Company’s assets and properties and the Company’s obligations under the 2025 Note are guaranteed by Pistol. The 2025 Note can be prepaid in whole or in part without penalty at any time. In the event that the Company receives any proceeds in connection with any fundraising or financing transaction (including any warrant exercises), it will be required to make a mandatory prepayment equal to the lesser of (i) forty percent (
In connection with the October 27, 2025 warrant exercise agreement (see Note 12 Stockholders' Equity), the Company prepaid approximately $
On July 28, 2026, the Company entered into an Exchange Agreement (the “2026 Exchange Agreement”) with the Lender. Pursuant to the 2026 Exchange Agreement, the Company and Lender agreed to (i) partition from the 2025 Note a new Promissory Note (the “July Partitioned Note”) in the original principal amount of $
On August 10, 2026, the Company entered into a second exchange agreement with the Lender. Pursuant to this exchange agreement, the Company and Lender agreed to (i) partition from the 2025 Note a new Promissory Note (the “August Partitioned Note”) in the original principal amount of $
On September 29, 2026, the Company entered into four separate exchange agreements with the Lender. Pursuant to these exchange agreements, the Company and Lender agreed to (i) partition from the 2025 Note four new Promissory Notes (the “Partitioned Notes”) in the aggregate original principal and interest amount of $
| 11. | EARNINGS (LOSS) PER SHARE - COMMON STOCK (“EPS”) |
The Company’s basic EPS is calculated using net income (loss) available to common shareholders and the weighted-average number of shares outstanding (as adjusted to reflect our 1-for-
For the three and nine months ended September 30, 2026 and 2025, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September 30, 2026 and 2025, shares issuable which could potentially dilute future earnings were as follows:
| Three Months ended | Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Stock options | ||||||||||||||||
| Warrants | ||||||||||||||||
| Total | ||||||||||||||||
| 12. | STOCKHOLDERS’ EQUITY |
Issuances of Common Stock
During the nine-month periods ended September 30, 2026, and 2025, there have not been any shares of common stock issued to anyone outside the Company, except as noted in this Note 12.
On June 18, 2021, the stockholders approved the Employee Stock Purchase Plan and on August 8, 2025, the stockholders approved the amendment to the plan to reserve an additional
Issuances of Restricted Stock
Restricted stock consists of shares of common stock that are subject to restrictions on transfer and risk of forfeiture until the fulfillment of specified conditions. The fair value of nonvested shares is determined based on the market price of the Company's common stock on the grant date. Nonvested stock is expensed ratably over the term of the restriction period.
During the nine-month periods ended September 30, 2026 and 2025, the Company issued
During the nine-month periods ended September 30, 2026 and 2025,
Share based compensation for the nine-month periods ended September 30, 2026 and 2025, was $
Issuances to Directors
During the nine-month periods ended September 30, 2026, and 2025, the Company issued
Issuance of Stock Options
During the nine-month periods ended September 30, 2026 and 2025, the Company issued options to purchase
On September 21, 2026, the Company issued a stock option to a new employee to purchase
The fair value of the option at date of issuance was estimated on the date of grant at $
Employees’ exercise options
During the nine-month periods ended September 30, 2026 and 2025,
Warrants
On August 10, 2026, the Company entered into a warrant exercise agreement (the “2026 Warrant Exercise Agreement”) with an existing institutional investor (the “Investor”) to exercise certain outstanding warrants to purchase an aggregate of
On October 27, 2025, the Company entered into and closed a warrant exercise agreement (the “2025 Warrant Exercise Agreement”) with the Investor to exercise certain outstanding warrants to purchase an aggregate of
On January 15, 2025, the Company entered into a warrant exercise agreement (the "January Warrant Exercise Agreement") with the Investor to exercise certain outstanding warrants to purchase an aggregate of
On September 12, 2024, the Company entered into a Warrant Exercise Agreement ("Inducement Agreement") with the Investor for the immediate exercise of certain outstanding warrants that the Company issued on October 30, 2023. Pursuant to the Inducement Agreement, the Investor agreed to exercise outstanding warrants to purchase an aggregate of
Exchange Agreements
On July 28, 2026, August 10, 2026 and September 29, 2026, the Company entered into six separate Exchange Agreements with the Lender. At September 30, 2026, the balance of the 2025 Note was repaid in full (see Note 10, Notes Payable).
| 13. | FAIR VALUES OF FINANCIAL INSTRUMENTS |
Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at, or approximate, fair value because of their short-term nature. The carrying value of the Company’s government loan payable approximates fair value as the interest rate related to the financial instruments approximated market.
| 14. | MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE |
During each of the three-month periods ended September 30, 2026, and 2025, customer accounted for
During each of the nine-month periods ended September 30, 2026, and 2025, customers accounted for
customers accounted for
| 15. | INCOME TAXES |
United States, Hong Kong and Nigeria
The Company recorded income tax expense for the three and nine months ended September 30, 2026 and 2025 because the estimated annual effective tax rate was . In determining the estimated annual effective income tax rate, the Company analyzes various factors, including projections of the Company’s annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, the ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives.
As of September 30, 2026 and December 31, 2025, the Company provided a full valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.
Spain
Due to the current loss for the nine months ended September 30, 2026, the Company did record income taxes.
| 16 | SEGMENT INFORMATION |
The Company operates as
The significant expenses that are regularly provided to the CODM are disclosed in the consolidated statements of operations as a part of the condensed consolidated net loss. See the condensed consolidated financial statements for all financial information regarding the Company’s operating segment.
See Note 3 for the Company’s revenues by geographic region.
The Company’s long-lived tangible assets are recognized on the Condensed Consolidated Balance Sheet are located in New Hampshire and Hong Kong. The Company’s operating lease right-of use assets recognized on the Condensed Consolidated Balance Sheet are located in Minnesota and New Hampshire.
| 17 | SUBSEQUENT EVENT |
On October 30, 2026, at the reconvened 2026 Annual Meeting of Stockholders, the Company’s stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “should,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generally identify forward-looking statements. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to migrate Swivel Secure customers to BIO-key and PortalGuard offerings; our ability to execute definitive agreements with Fiber Food Systems and/or its customers to utilize our access management solutions; our ability to integrate our solutions into any of Fiber Food Systems' offerings; fluctuations in foreign currency exchange rates; the duration and extent of continued hostilities in Ukraine and its impact on our European customers; the impact of tariffs and other trade barriers which may make it more costly for us to import inventory from China and Hong Kong and certain product components from South Korea; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence of non-compliance with the Securities and Exchange Commission (“SEC”)
and Nasdaq periodic reporting requirements due to late filings; the commercial and reputational risks and impact on the trading and liquidity of our common stock due to the suspension of trading of our common stock on the Nasdaq Capital Market, the monitoring of our compliance by the Nasdaq Hearings Panel through July 6, 2027, or in the event that the trading of our common stock is suspended due to non-compliance with existing and or proposed continued listing standards of the Nasdaq Stock Market; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to maintain effective controls over financial reporting, statements of assumption underlying any of the foregoing, and numerous other matters of national, regional and global scale, including those set forth under the caption “Risk Factors” in our Annual Report on Form 10-K/A for the year ended December 31, 2025 and other filings with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, presently or in the future. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information,
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Management’s Discussion and Analysis of Financial Condition and Results of Operations is provided as a supplement to and should be read in conjunction with our unaudited condensed consolidated financial statements and related information contained herein and our audited financial statements as of December 31, 2025.
Overview
BIO-key International, Inc. (the “Company,” “BIO-key,” “we,” or “us”) is a leading identity access management, or IAM, platform provider for the enterprise and large-scale customer and civil ID solutions. Built to leverage BIO-key’s world-class biometric core platform among seventeen strong authentication factors, BIO-key PortalGuard and hosted PortalGuard IDaaS platforms that enable our customers to securely and easily assure that only the right people can access the right systems. PortalGuard goes beyond traditional multifactor authentication (MFA) solutions by addressing functional gaps, such as allowing roving users to biometrically authenticate at any workstation without using their phones or tokens eliminating unauthorized account delegation, detecting duplicate users, and accommodating in-person identification.
Our customers use BIO-key every day to securely access a variety of cloud, mobile and web applications, on-premise and cloud-based servers from all of their devices. Employees, contractors, students and faculty sign in through PortalGuard to seamlessly and securely access the applications they need to do their important work, without relying on personal phone use or per-user tokens. Organizations use our platform to securely collaborate with their supply chain and partners, and to provide their customers with flexible, resilient user experiences online or in-person.
Large-scale customer and civil ID customers use our scalable biometric management platform and FBI-certified scanner hardware to manage enrollment, de-duplication and authentication for millions of users. One large bank has enrolled and identifies over 21.7 million of their customers using BIO-key fingerprint biometrics in branches on a daily basis.
PortalGuard and Identity-Bound Biometrics, or IBB, deliver unique value to enterprises who find that mainstream MFA solutions do not adequately address their workforce use cases. PortalGuard operates as a single MFA user experience, providing a wide set of authentication choices to meet every use case. We sell our branded biometric and Fast Identity Online, or FIDO, authentication hardware as accessories to our IAM platforms, so that customers can have a single vendor providing all components of their IAM solution. We do not mandate the use of BIO-key hardware with our software and services. Our National Institute of Standards, and Technology, or NIST, certified fingerprint biometric platform is unique in that it supports interoperable mixing and matching combinations of different manufactures’ fingerprint scanners in a deployment, so that the right scanner can be selected for the right use case, without mandating the use of a particular scanner.
Security-conscious software developers leverage our platform APIs and federation interfaces to securely and efficiently embed biometric and MFA identity capabilities into their software. Our approach to IDaaS allows our customers to efficiently scale their security and identity infrastructures to protect both internal cloud workforce- and external customer-facing applications.
In 2022, we expanded our product offerings and customer base when we acquired Swivel Secure, a Madrid, Spain based provider of IAM solutions. Until the fourth quarter of 2024, Swivel Secure was the exclusive distributor of AuthControl Sentry, AuthControl Enterprise, and AuthControl MSP product line in Europe, Africa and the Middle East, or EMEA, excluding the United Kingdom and Ireland. Swivel Secure, now operates as BIO-key EMEA and maintains a direct sales force with offices in Madrid, Spain and Lisbon, Portugal, and sells only BIO-key products.
We operate a software as a service, or SaaS, business model with customers subscribing to term use of our software for annual recurring revenue. We sell our products directly through our field and inside sales teams, as well as indirectly through our network of channel partners including resellers, system integrators, master agents and other distribution partners. Our subscription fees include a term license of hosted or on-premise product and technical support and maintenance of our platform. We base subscription fees primarily on the products used and the number of users enrolled in our platform. We generate subscription fees pursuant to noncancelable contracts with a weighted average duration of approximately one year.
Strategic Outlook
We plan to have a more significant role in the IAM market which continues to expand. We plan to continue to offer customers a suite of authentication options that complement our biometric solutions. The more well-rounded offerings of authentication options will allow customers to customize their approach to authentication all under one umbrella.
We expect to grow our business within government services and highly-regulated industries in which we have historically had a strong presence including financial services, higher education, and healthcare. We believe that continued heightened security and privacy requirements in these industries, and as colleges and universities continue operating in remote environments, we will generate increased demand for security solutions, including biometrics. In addition, we expect that the compatible, yet superior portable biometric user experience offered by our technology for Windows 11 users will accelerate the demand for our computer network log-on solutions and fingerprint readers. Through value add-offerings via direct sales, resellers, and strategic partnerships with leading higher education platform providers, we will continue to grow our installed base.
Our primary sales strategies are focused on (i) increased marketing efforts into the IAM market, (ii) dedicated pursuit of large-scale identification projects across the globe and (iii) growing our channel alliance program which we have grown to more than eighty-five participants and continues to generate incremental revenues.
A second component of our growth strategy is to pursue strategic acquisitions of select businesses and assets in the IAM space. In furtherance of this strategy, we are active in the industry and regularly evaluate businesses that we believe will either provide an entry into new market verticals or be synergistic with our existing operations and in either case, be accretive to earnings. We cannot provide any assurance as to whether we will be able to complete any acquisition and if completed, successfully integrate any business we acquire into our operations.
Recent Developments
The current trend of continued remote work environments increases the risk of unauthorized users, phishing attacks, and hackers who are eager to take advantage of the challenges of securing remote workers. A growing trend of security incidents that highlight potential cybersecurity vulnerabilities, additional regulatory requirements, and increasingly stringent Cyber Insurance underwriting standards that mandate enhanced security solutions has resulted in many businesses requiring MFA for their employees, partners and customers to access their business systems and data. We believe that biometrics should continue to play a key role in remote user authentication. In addition, the growing commercial prevalence of AI agents creates a new identity challenge to verify who authorized an agent’s actions which we believe out biometric solutions can address.
Critical Accounting Policies and Estimates
For detailed information regarding our critical accounting policies and estimates, see our financial statements and notes thereto included in this Report and in our Annual Report on Form 10-K/A for the year ended December 31, 2025. There have been no material changes to our critical accounting policies and estimates from those disclosed in our most recent Annual Report on Form 10-K/A.
Recent Accounting Pronouncements
For detailed information regarding recent account pronouncements, see Notes to Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
RESULTS OF OPERATIONS
THREE MONTHS ENDED September 30, 2026 AS COMPARED TO September 30, 2025
Consolidated Results of Operations - Percent Trend
| Three Months Ended September 30, |
||||||||
| 2026 |
2025 |
|||||||
| Revenues |
||||||||
| Services |
13 | % | 17 | % | ||||
| License fees |
86 | % | 59 | % | ||||
| Hardware |
1 | % | 24 | % | ||||
| Total Revenues |
100 | % | 100 | % | ||||
| Costs and other expenses |
||||||||
| Cost of services |
5 | % | 5 | % | ||||
| Cost of license fees |
4 | % | 5 | % | ||||
| Cost of hardware |
1 | % | 28 | % | ||||
| Cost of hardware - reserve |
0 | % | -15 | % | ||||
| Total Cost of Goods Sold |
10 | % | 23 | % | ||||
| Gross profit |
90 | % | 77 | % | ||||
| Operating expenses |
||||||||
| Selling, general and administrative |
103 | % | 90 | % | ||||
| Research, development and engineering |
43 | % | 44 | % | ||||
| Total Operating Expenses |
146 | % | 134 | % | ||||
| Operating loss |
-56 | % | -57 | % | ||||
| Other expense |
-4 | % | -5 | % | ||||
| Loss before provision for income tax |
-60 | % | -62 | % | ||||
| Provision for income tax |
0 | % | 0 | % | ||||
| Net loss |
-60 | % | -62 | % | ||||
Revenues and cost of goods sold
| Three Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Revenues |
||||||||||||||||
| Service |
$ | 195,128 | $ | 268,113 | $ | (72,985 | ) | -27 | % | |||||||
| License |
1,275,249 | 917,951 | 357,298 | 39 | % | |||||||||||
| Hardware |
12,404 | 363,642 | (351,238 | ) | -97 | % | ||||||||||
| Total Revenue |
$ | 1,482,781 | $ | 1,549,706 | $ | (66,925 | ) | -4 | % | |||||||
| Three Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Cost of Goods Sold |
||||||||||||||||
| Service |
$ | 76,704 | $ | 80,702 | $ | (3,998 | ) | -5 | % | |||||||
| License |
55,953 | 74,077 | (18,124 | ) | -24 | % | ||||||||||
| Hardware |
15,184 | 434,834 | (419,650 | ) | -97 | % | ||||||||||
| Hardware - reserve |
(4,468 | ) | (231,625 | ) | 227,157 | 98 | % | |||||||||
| Total COGS |
$ | 143,373 | $ | 357,988 | $ | (214,615 | ) | -60 | % | |||||||
Revenues
For the three months ended September 30, 2026, and 2025, service revenues included approximately $195,000 and $263,000, respectively, of recurring maintenance and support revenue, and approximately $0 and $5,000 respectively, of non-recurring custom services revenue. Recurring service revenue decreased $68,000 or 26% in 2026 period which was due to a few non-renewals and the timing of renewals of service agreements. Non-recurring custom services decreased $5,000 due to a decrease in customization. Overall, service revenues decreased to $195,128 as compared to $268,113 in the corresponding period in 2025.
For the three months ended September 30, 2026, license revenue increased $357,298 or 39% to $1,275,249 from $917,951 in the corresponding period in 2025 as several new customers deployed new licenses in 2026.
For the three months ended September 30, 2026, hardware sales decreased 97% to $12,404 from $363,642 in the corresponding period in 2025. The decrease was due to several new customers with license-only orders.in the 2026 period, and one large deployment from one long-term customer and several long-term customers expanding their deployments of biometric cybersecurity solutions in 2025.
Costs and other expenses
For the three months ended September 30, 2026, cost of service decreased $3,998 or 5% to $76,704 from $80,702 in the three months ended September 30, 2025. For the three months ended September 30, 2026, license costs decreased 24% to $55,953 from $74,077 in the three months ended September 30, 2025. For the three months ended September 30, 2026, hardware costs decreased to net cost of $10,716 (after giving effect to the $4,468 reversal of the previously fully reserved inventory) from $203,209 in the three months ended September 30, 2025, for a net decrease of 95%, based on the decrease in hardware revenue, disposal of some scrap in fabricated assemblies, and different models of hardware shipped.
Selling, general and administrative
| Three Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Selling, general and administrative |
$ | 1,524,583 | $ | 1,400,288 | $ | 124,295 | 9 | % | ||||||||
Selling, general and administrative expenses for the three months ended September 30, 2026, increased 9% from $1,400,288 in the corresponding period in 2025 to $1,524,583 in the current quarter. The increases included personnel and related costs in administration, and costs incurred in connection with our annual meeting, including the proxy supplement and adjourned meeting sessions.
Research, development and engineering
| Three Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Research, development, and engineering |
$ | 635,038 | $ | 683,620 | $ | (48,582 | ) | -7 | % | |||||||
For the three months ended September 30, 2026, research, development, and engineering costs decreased 7% to $635,038 compared to $683,620 in the corresponding period in 2025. The decrease consisted primarily of personnel costs.
Other income (expense)
| Three Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Interest income |
$ | 678 | $ | 515 | $ | 163 | 32 | % | ||||||||
| Loan fee amortization |
(62,500 | ) | (60,000 | ) | (2,500 | ) | -4 | % | ||||||||
| Interest expense |
(4,048 | ) | (13,174 | ) | 9,126 | 69 | % | |||||||||
| Other income (expense) |
$ | (65,870 | ) | $ | (72,659 | ) | $ | 6,789 | 9 | % | ||||||
Other income (expense) for the three months ended September 30, 2026 consisted of interest income of $678, interest expense of $4,048 on the note payable, and a loan fee amortization amount of $62,500. Other income (expense) for the three months ended September 30, 2025 consisted of interest income of $515 and interest expense of $13,174 comprised of the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $60,000.
nine MONTHS ENDED September 30, 2026 AS COMPARED TO September 30, 2025
Consolidated Results of Operations - Percent Trend
| Nine Months Ended September 30, |
||||||||
| 2026 |
2025 |
|||||||
| Revenues |
||||||||
| Services |
12 | % | 18 | % | ||||
| License fees |
70 | % | 58 | % | ||||
| Hardware |
18 | % | 24 | % | ||||
| Total Revenues |
100 | % | 100 | % | ||||
| Costs and other expenses |
||||||||
| Cost of services |
4 | % | 6 | % | ||||
| Cost of license fees |
4 | % | 5 | % | ||||
| Cost of hardware |
20 | % | 22 | % | ||||
| Cost of hardware - reserve |
-14 | % | -10 | % | ||||
| Total Cost of Goods Sold |
14 | % | 23 | % | ||||
| Gross profit |
86 | % | 77 | % | ||||
| Operating expenses |
||||||||
| Selling, general and administrative |
79 | % | 92 | % | ||||
| Research, development and engineering |
34 | % | 39 | % | ||||
| Total Operating Expenses |
113 | % | 131 | % | ||||
| Operating loss |
-27 | % | -54 | % | ||||
| Other expense |
-3 | % | -5 | % | ||||
| Loss before provision for income tax |
-30 | % | -59 | % | ||||
| Provision for income tax |
0 | % | 0 | % | ||||
| Net loss |
-30 | % | -59 | % | ||||
Revenues and cost of goods sold
| Nine Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Revenues |
||||||||||||||||
| Service |
$ | 674,516 | $ | 862,707 | $ | (188,191 | ) | -22 | % | |||||||
| License |
3,870,487 | 2,822,796 | 1,047,691 | 37 | % | |||||||||||
| Hardware |
1,003,302 | 1,168,269 | (164,967 | ) | -14 | % | ||||||||||
| Total Revenue |
$ | 5,548,305 | $ | 4,853,772 | $ | 694,533 | 14 | % | ||||||||
| Cost of Goods Sold |
||||||||||||||||
| Service |
234,918 | 297,147 | (62,229 | ) | -21 | % | ||||||||||
| License |
204,159 | 233,450 | (29,291 | ) | -13 | % | ||||||||||
| Hardware |
1,133,035 | 1,080,109 | 52,926 | 5 | % | |||||||||||
| Hardware - reserve |
(806,488 | ) | (509,040 | ) | (297,448 | ) | 58 | % | ||||||||
| Total COGS |
$ | 765,624 | $ | 1,101,666 | $ | (336,042 | ) | -31 | % | |||||||
Revenues
For the nine months ended September 30, 2026, and 2025, service revenues included approximately $652,000 and $799,000, respectively, of recurring maintenance and support revenue, and approximately $23,000 and $64,000 respectively, of non-recurring custom services revenue. Recurring service revenue decreased $147,000 or 18% in the 2026 period due to a few non-renewals and the timing of renewals of service agreements. Non-recurring custom services decreased $41,000 due to a decrease in customization. Overall, service revenues decreased to $674,516 as compared to $862,707 in the corresponding period in 2025.
For the nine months ended September 30, 2026, license revenue increased $1,047,691 or 37% to $3,870,487 from $2,822,796 in the corresponding period in 2025 as several new customers initiated license deployments in 2026.
For the nine months ended September 30, 2026, hardware sales decreased 14% to $1,003,302 from $1,168,269 in the corresponding period in 2025. The decrease was due several new customers with license-only orders.in the third quarter of 2026, that slowed the increase trend.
Costs and other expenses
For the nine months ended September 30, 2026, cost of service decreased $62,229 or 21% to $234,918 from $297,147 in the nine months ended September 30, 2025. For the nine months ended September 30, 2026, license costs decreased to $204,159 from $233,450 in the nine months ended September 30, 2025. For the nine months ended September 30, 2026, hardware costs decreased to net cost of $326,547 (after giving effect to the $806,488 reversal of the fully reserved shipped inventory) from $571,069 (after giving effect to the $509,040 reversal of the fully reserved shipped inventory) in the nine months ended September 30, 2025, for a net decrease of 43%.
Selling, general and administrative
| Nine Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Selling, general and administrative |
$ | 4,397,676 | $ | 4,453,362 | $ | (55,686 | ) | -1 | % | |||||||
Selling, general and administrative expenses for the nine months ended September 30, 2026, decreased 1% from $4,453,362 in the corresponding period in 2025 to $4,397,676. The decreases included reductions in professional services fees.
Research, development and engineering
| Nine Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Research, development and engineering |
$ | 1,892,337 | $ | 1,915,422 | $ | (23,085 | ) | -1 | % | |||||||
For the nine months ended September 30, 2026, research, development, and engineering costs decreased 1% to $1,892,337 compared to $1,915,422 in the corresponding period in 2025. The decrease consisted primarily of professional services and personnel costs changes.
Other income (expense)
| Nine Months Ended |
||||||||||||||||
| September 30, |
||||||||||||||||
| 2026 |
2025 |
$ Change |
% Change |
|||||||||||||
| Interest income |
$ | 1,740 | $ | 2,610 | $ | (870 | ) | -33 | % | |||||||
| Loan fee amortization |
(104,166 | ) | (180,000 | ) | 75,834 | 42 | % | |||||||||
| Interest expense |
(58,214 | ) | (74,722 | ) | 16,508 | 22 | % | |||||||||
| Other income (expense) |
$ | (160,640 | ) | $ | (252,112 | ) | $ | 91,472 | 36 | % | ||||||
Other income (expense) for the nine months ended September 30, 2026 consisted of interest income of $1,740, interest expense of $58,214 on the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $104,166. Other income (expense) for the nine months ended September 30, 2025 consisted of interest income of $2,610 and interest expense of $74,722 comprised of the note payable and the government loan through the BBVA bank, and a loan fee amortization amount of $180,000.
LIQUIDITY AND CAPITAL RESOURCES
Cash Flows
Operating activities overview
| Net cash used in operations during the nine months ended September 30, 2026 was $2,634,682. Items of note included: |
| ● |
Net positive cash flows related to adjustments for non-cash expenses of approximately $655,000. |
| ● |
Net positive cash flows related to inventory of approximately $810,000. |
| ● |
Negative cash flows related to changes in accounts receivable, capitalized contract costs, prepaid expenses, accounts payable, deferred revenue and accrued liabilities of approximately $1,625,180, due to working capital management. |
Financing activities overview
Net cash provided by financing activities during the nine months ended September 30, 2026 was $2,310,769 consisting of the repayment of $38,179 government loan through the BBVA bank, offset by receipt of $7,660 for purchases under the Employee Stock Purchase Plan and proceeds from exercise of warrants of $2,510,436, offset by offering costs of $169,148.
Investing activities overview
There was $7,819 cash used in investing activities during the nine months ended September 30, 2026.
Liquidity and Capital Resources
Since our inception, our capital needs have been met mainly through proceeds from the sale of equity and debt securities, and revenue. We expect capital expenditures to be less than $100,000 during the next twelve months.
The following sets forth our sources of liquidity during the previous two years through the date of this filing:
On August 11, 2026, we closed a transaction with an existing investor to exercise outstanding warrants to purchase an aggregate of 618,334 shares of common stock in consideration for reducing the per share exercise price from $10.20 to $4.06 and issuing additional warrants to the investor to purchase up to an aggregate of 1,236,668 shares of common stock at exercise price of $4.06 per share. The foregoing resulted in gross proceeds of approximately $2.5 million, prior to deducting placement agent fees and estimated offering expenses.
On October 27, 2025, we entered into and closed a warrant exercise agreement (the “2025 Warrant Exercise Agreement”) with an existing institutional investor to exercise certain outstanding warrants to purchase an aggregate of 309,167 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026). The warrants were originally issued on January 15, 2025 and had an exercise price of $21.50 per share. In consideration for the immediate exercise of these warrants, we issued new unregistered warrants to purchase up to an aggregate of 618,334 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026) which were amended and exercised in full pursuant to the transaction described in the preceding paragraph. We realized gross proceeds of approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses.
On September 30, 2025, we entered into and closed a note purchase agreement which provided for the issuance of a $1,130,000 principal amount senior secured promissory note (the "2025 Note"). This resulted in net proceeds of approximately $1,000,000 after deducting estimated offering expenses, and the original issue discount. The 2025 Note was due eighteen months (18) following the date of issuance, accrues interest at a rate of nine percent (9%) per annum, and commencing six months after the date of issuance, the lender had the right to redeem up to $135,000 of principal amount each month. In connection with the October 27, 2025 warrant exercise agreement described above, we prepaid approximately $455,000 of the amount due under the 2025 Note.
On July 28, 2026, we entered into an Exchange Agreement (the “2025 Exchange Agreement”) with the Lender of the 2025 Note. Pursuant to the 2025 Exchange Agreement, we agreed to (i) partition from the 2025 Note a new Promissory Note (the “Partitioned Note”) in the original principal amount of $200,000, (ii) cause the outstanding balance of the 2025 Note to be reduced by $200,000 and (iii) exchange the Partitioned Note for 43,308 shares of the Company’s Common Stock. On August 10, 2026, we entered into a second exchange agreement with the Lender of the 2025 Note. Pursuant to this exchange agreement, we agreed to (i) partition from the 2025 Note a new Promissory Note (the “Second Partitioned Note”) in the original principal amount of $150,000, (ii) cause the outstanding balance of the 2025 Note to be reduced by $150,000 and (iii) exchange the Second Partitioned Note for 37,792 shares of the Company’s Common Stock. On September 29, 2026, we entered into four separate exchange agreements with the Lender. Pursuant to these exchange agreements, we agreed to (i) partition from the 2025 Note four new Promissory Notes in the aggregate original principal and interest amount of $416,316, (ii) cause the outstanding balance of the 2025 Note to be paid in full and (iii) exchange these new promissory notes for 247,805 shares of the Company’s Common Stock.
On January 15, 2025, we entered into a warrant exercise agreement (the “January 2025 Warrant Exercise Agreement”) with an existing investor to exercise certain outstanding warrants to purchase an aggregate of 206,112 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026), at an exercise price of $18.50 per share which were originally issued to the investor on September 12, 2024 (the "Existing Warrants"). In consideration for the exercise of the Existing Warrants, the investor received new warrants to purchase up to an aggregate of 309,167 shares of Common Stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026) which were amended and exercised in full pursuant to the 2025 Warrant Exercise Agreement which is more fully described above. The gross proceeds to the Company were approximately $3.8 million, prior to deducting placement agent fees and estimated offering expenses.
On September 12, 2024, we entered into a warrant exercise agreement with an existing investor to exercise certain outstanding warrants to purchase an aggregate of 103,056 shares of common stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026). The warrants were originally issued to the Investor on October 31, 2023 and had an original exercise price of $31.50 per share. In consideration for the immediate exercise of the warrants, we reduced the exercise price of the warrants to $18.50 per share and issued to the Investor new warrants to purchase up to an aggregate of 206,112 shares of Common Stock (as adjusted to reflect our 1-for-10 reverse stock split, which was effective April 30, 2026) which were amended and exercised in full pursuant to the January 2025 Warrant Exercise Agreement which is more fully described above. The foregoing transaction resulted in gross proceeds of approximately $1.9 million prior to deducting placement agent fees and estimated offering expenses.
On June 24, 2024, we entered into and closed a note purchase agreement which provided for the issuance of a $2,360,000 principal amount senior secured promissory note (the "2024 Note"). This resulted in gross proceeds of approximately $1,826,000 after deducting placement agent fees, estimated offering expenses, and the original issue discount. The 2024 Note was due eighteen months (18) following the date of issuance, accrued interest at a rate of nine percent (9%) per annum, and commencing six months after the date of issuance, the lender had the right to redeem up to $270,000 of principal amount each month. In connection with the September 12, 2024 warrant exercise agreement described above, we prepaid approximately $762,600 of the amount due under the 2024 Note. As of the date of this report, the loan has been paid in full. For a more complete description of the 2024 Note, please see Note 10 to Our Condensed Consolidated Financial Statements included in Part I Item 1 of this report.
We are party to an accounts receivable factoring arrangement with a financial institution (the “Factor”) which has been extended to October 31, 2027 and may be discontinued at that time. Pursuant to the terms of the arrangement, from time to time, we sell to the Factor a minimum of $150,000 per quarter of certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. The Factor remits 35% of the foreign and 75% of the domestic accounts receivable balance to us, with the remaining balance, less fees, forwarded to us once the Factor collects the full accounts receivable balance from the customer. In addition, from time to time, we receive over advances from the Factor. Factoring fees range from 2.75% to 15% of the face value of the invoice factored and are determined by the number of days required for collection of the invoice. We expect to continue to use this factoring arrangement periodically to assist with our general working capital requirements due to contractual requirements.
Liquidity outlook
At September 30, 2026, our total cash and cash equivalents were $2,219,428, as compared to $2,694,663 at December 31, 2025. At September 30, 2026, we had a working capital of approximately $3,140,000.
As discussed above, we have historically financed our operations through access to the capital markets by issuing secured and convertible debt securities, convertible preferred stock, common stock, warrants, and through factoring receivables. We currently require approximately $750,000 per month to conduct our operations, a monthly amount that we have been unable to consistently achieve through revenue generation. We also have approximately $2.1 million of inventory (currently reserved) initially purchased for projects in Nigeria. We continue to explore other markets and opportunities to sell the product to generate additional cash. If we are unable to generate sufficient revenue and positive cash flow from operations or liquidation of existing inventory to fund current operations and execute our business plan, we will need to obtain additional third-party financing over the next twelve months.
Our long-term viability and growth will depend upon the successful commercialization of our technologies and our ability to obtain adequate financing. To the extent that we require such additional financing, no assurance can be given that any form of additional financing will be available on terms acceptable to us, that adequate financing will be obtained to meet our needs, or that such financing would not be dilutive to existing stockholders. If available financing is insufficient or unavailable or we fail to continue to generate sufficient revenue, we may be required to further reduce operating expenses, delay the expansion of operations, be unable to pursue merger or acquisition candidates, or in the extreme case, not continue as a going concern.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company, we are not required to provide the information required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2026. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of September 30, 2026, our CEO and CFO concluded that, as of such date, our disclosure controls and procedures were ineffective at a reasonable assurance level.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of the date of this report, we are not a party to any pending lawsuits.
As a smaller reporting company, we are not required to provide the information required by this Item.
Investors are encouraged to consider the risks described in our 2025 Form 10-K/A, our Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this Report, and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On July 28, 2026, the Company issued 43,308 shares of its common stock to Streeterville Capital, LLC in exchange for a promissory note in the original principal amount of $200,000 partitioned from the 2025 Note. On August 10, 2026, the Company issued 37,792 shares of its common stock to Streeterville Capital, LLC in exchange for a promissory note in the original principal amount of $150,000 partitioned from the 2025 Note. The forgoing shares were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
During the three months ended September 30, 2026, of our directors or “officers” (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Securities and Exchange Commission Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIO-key International, Inc. |
||
| Dated: November 13, 2026 |
/s/ Michael W. DePasquale |
|
| Michael W. DePasquale |
||
| Chief Executive Officer |
||
| (Principal Executive Officer) |
||
| Dated: November 13, 2026 | /s/ Cecilia C. Welch |
|
| Cecilia C. Welch |
||
| Chief Financial Officer |
||
| (Principal Financial Officer) |
Exhibit 31.1
CERTIFICATION
I, Michael W. DePasquale, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of BIO-key International, Inc. (the “Company”); |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; |
|
4. |
The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have: |
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
||
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
||
|
(c) |
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
||
|
(d) |
Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and |
|
5. |
The Company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): |
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and |
|
|
|
||
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. |
|
Dated: November 13, 2026 |
||
|
/s/ Michael W. DePasquale |
||
|
Michael W. DePasquale |
||
|
Chief Executive Officer |
||
Exhibit 31.2
CERTIFICATION
I, Cecilia C. Welch, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q of BIO-key International, Inc. (the “Company”); |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; |
|
4. |
The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have: |
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
||
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
||
|
(c) |
Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
||
|
(d) |
Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and |
|
5. |
The Company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions): |
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and |
|
|
|
||
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting. |
|
Dated: November 13, 2026 |
||
|
/s/ Cecilia C. Welch |
||
|
Cecilia C. Welch |
||
|
Chief Financial Officer |
||
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BIO-key International, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael W. DePasquale, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
BIO-KEY INTERNATIONAL, INC. |
|||
|
By: |
/s/ Michael W. DePasquale |
||
|
Michael W. DePasquale |
|||
|
Chief Executive Officer |
|||
|
Dated: November 13, 2026 |
|||
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BIO-key International, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Cecilia Welch, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
BIO-KEY INTERNATIONAL, INC. |
|||
|
By: |
/s/ Cecilia C. Welch |
||
|
Cecilia C. Welch |
|||
|
Chief Financial Officer |
|||
|
Dated: November 13, 2026 |
|||